BioNTech enters the TROP2 space

BioNTech has followed an April deal with DualityBio with the acquisition of ex-China rights to the Chinese group's TROP2-targeted antibody-drug conjugate DB-1305. The molecule is being evaluated in a first-in-human trial in advanced solid tumours including NSCLC, SCLC, HR+/HER2- breast cancer and TNBC. The agreement expands on the original deal from April 2023 where BioNTech licensed ex-China rights to DB-1303 (anti-HER2 ADC) and DB-1311 (anti-B7-H3). DualityBio received $170 million up front and is eligible to receive up to $1.5 billion in milestone payments for both assets. Last month BeiGene entered into a $1.3 billion deal with DualityBio for the exclusive option to a preclinical ADC program for select solid tumours. Anti-TROP-2 projects in clinical developmentProjectCompanyClinical enrolmentTrodelvyGilead82 trials, 15,245 patientsDatopotamab deruxtecanDaiichi Sankyo/AstraZeneca18 trials, 8,537 patientsSacituzumab tirumotecanKelun/Merck & Co11 trials, 1,962 patientsMHB036CMinghui Pharmaceutical2 trials, 400 patientsBIO-106BiOneCure1 trial, 332 patientsSHR-A1921Jiangsu Hengrui Medicine4 trials, 311 patientsLCB84LegoChem1 trial, 300 patientsDB-1305DualityBio/BioNTech1 trial, 235 patientsSTI-3258Sorrento2 trials, 207 patientsBAT8008Bio-Thera2 trials, 182 patientsIBI130Innovent1 trial, 182 patientsFZ-AD004Shanghai Fudan-Zhangjiang1 trial, 121 patientsBL-M02D1SystImmune3 trials, 112 patientsFDA018Shanghai Fudan-Zhangjiang1 trial, 78 patientsMT-302*Myeloid Therapeutics1 trial, 48 patientsJS108Shanghai Junshi Bioscience1 trial, 25 patientsNote: *mRNA encoding in vivo Car against TROP2, delivered in LNP; all others are ADCs. Source: OncologyPipeline.